By Michael McCaughan
The House Government Oversight and Government Reform Committee is sifting through some very valuable data—information about prescritpion drug prices under...
Sticker Shock: The Debate Over Making Part D Pricing Data Public
A Congressional committee is sifting through drug rebate data from 12 big Medicare Part D plans. According to Congress' accounting arm, making the data public will cost the government as much as $10 billion dollars. But industry better be nervous about what happens next.
More from Market Access
More from Pink Sheet
• By
A new PBM reform package has familiar provisions, but stakeholders want it to move as a stand-alone bill, rather than as part of a larger legislative vehicle.
• By
The European Medicines Agency’s, human medicines committee, the CHMP, is this week poised to issue opinions on potential marketing approvals for 17 products.
• By
The European Medicines Agency is expected to decide whether to recommend EU-wide marketing authorization for six orphan-designated medicines that are all already approved in the US.